Women’s Health Report Assesses first-in-class innovation with focus on endometriosis, polycystic ovarian syndrome and cervical intraepithelial neoplasia

This report assesses first-in-class innovation across the women’s health therapy area, with a particular focus on three key indications: endometriosis, polycystic ovarian syndrome (PCOS) and cervical intraepithelial neoplasia (CIN).

Pune, India - March 14, 2018 /MarketersMedia/ —

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population. Despite this, the women’s health market is relatively small. This reflects diagnostic barriers and high levels of non-treatment for women’s health disorders, as well as high levels of genericization and relatively limited innovation within recent decades.
Access Report Details at: https://www.themarketreports.com/report/frontier-pharma-womens-health-an-expanding-therapy-area-with-endometriosis-therapies-prominent-among-the-first-in-class-pipeline
Scope
• Many women’s health disorders are highly prevalent. How do epidemiology trends vary for endometriosis, PCOS and CIN?
• Innovation within women’s health has been relatively limited over recent decades. What are the most prominent unmet needs across this therapy area?
• There are 261 pipeline programs in active development for women’s health. What proportion of these products are first-in-class? How does first-in-class innovation vary by indication, development stage and molecular target class?
• Although the first-in-class pipeline is relatively modest in size it is considerably diverse with eight distinct molecular target classes represented. Which first-in-class targets have been identified as most promising for women’s health conditions?
• Over 200 licensing deals relating to women’s health have been completed since 2006. Do women’s health products typically attract high deal values? Which first-in-class products have prior deal involvement?
Inquire for more details at: https://www.themarketreports.com/report/ask-your-query/987871
Reasons To Buy
• Understand the current clinical and commercial landscape. This includes a comprehensive study of symptoms, epidemiology, etiology, pathophysiology, co-morbidities and complications, diagnosis and treatment options.
• Visualize the composition of the women’s health market in terms of dominant molecule types and molecular targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
• Analyze the women’s health pipeline and stratify by stage of development, molecule type and molecular target.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
• Recognize commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals, and identifying women’s health therapies that have not yet been involved in deals and may offer potential investment opportunities.
Get this report at: https://www.themarketreports.com/report/buy-now/987871

Contact Info:
Name: Shirish Gupta
Email: sales@themarketreports.com
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/womens-health-report-assesses-first-in-class-innovation-with-focus-on-endometriosis-polycystic-ovarian-syndrome-and-cervical-intraepithelial-neoplasia/314337

For more information, please visit https://www.themarketreports.com/report/frontier-pharma-womens-health-an-expanding-therapy-area-with-endometriosis-therapies-prominent-among-the-first-in-class-pipeline%20%20

Source: MarketersMedia

Release ID: 314337

Latest News

Britain's Prince Philip, 97, recovers after Land Rover crash

Jan 19, 2019

LONDON — Queen Elizabeth II's 97-year-old husband Prince Philip was recovering at the royal Sandringham estate after the Land Rover he was driving rolled over on its side in a collision with another vehicle. An alarming photo showing Philip's toppled black Land Rover dominated the front pages Friday of Britain's tabloids. The Daily Mirror's headline read: "Philip, 97, cheats death in crash." Buckingham Palace said Philip received a "precautionary checkup" at the Queen Elizabeth Hospital in King's Lynn on Friday and was found to have "no injuries of concern." Witness Roy Warne told the BBC he was driving home from...

Ryanair lowers profit forecast amid tough competition

Jan 19, 2019

LONDON — Budget airline Ryanair, Europe's biggest carrier by passengers, has warned its profits will be lower than expected — the second such downgrade in four months — because of weaker fares over the winter. The company said Friday it expects full-year profit of between 1 billion euros and 1.1 billion euros, down from a range of 1.1 billion euros to 1.2 billion euros previously. It said that while traffic is up, winter fares are expected to fall 7 percent. CEO Michael O'Leary noted there was stiff competition and expects some rival budget carriers to fall out of the market....

Prince Philip, queen's husband, uninjured after car accident

Jan 19, 2019

LONDON — Queen Elizabeth II's husband, Prince Philip, was involved in a car crash Thursday while driving in rural England but was not injured. Buckingham Palace said Philip, 97, was checked by a doctor after the accident and determined to be fine. The palace said the two-car accident happened Thursday afternoon near Sandringham Estate, the queen's country retreat in eastern England. Witnesses told the BBC Philip appeared "very shocked" and shaken after the collision, which caused the Land Rover he was driving to overturn. Norfolk Police said the drivers of both cars, a Land Rover and a Kia, were given...

AP Exclusive: UN health chief orders probe into misconduct

Jan 19, 2019

LONDON — The head of the World Health Organization has ordered an internal investigation into allegations the U.N. health agency is rife with racism, sexism and corruption, after a series of anonymous emails with the explosive charges were sent to top managers last year. Three emails addressed to WHO directors — and obtained by the Associated Press — complained about "systematic racial discrimination" against African staffers and alleged other instances of wrongdoing, including claims that some of the money intended to fight Ebola in Congo was misspent. Last month, WHO Director-General Tedros Adhanom Ghebreyesus told staffers he had instructed the...

The Latest: WHO confirms internal misconduct probe underway

Jan 19, 2019

LONDON — The Latest on misconduct allegations at the World Health Organization (all times local): 6:15 p.m. The World Health Organization has confirmed it is investigating allegations of misconduct following an Associated Press story that revealed its chief ordered an internal probe to examine explosive charges made in emails to the agency's top managers. The U.N. health agency said in a statement issued Thursday that charges of racism, sexism and corruption "are being investigated according to WHO's established procedures." The statement says the allegations had been circulating internally and addressed by WHO Director-General Tedros Adhanom Ghebreyesus at several staff meetings....

Sign up now!